Non-small-cell lung cancer (NSCLC) is an increasing global challenge, especially in low-income countries. Most guidelines for the management of advanced-stage NSCLC have limited effect in countries with resource constraints. Following a systematic literature search, we present an overview of the management of advanced-stage NSCLC in the first-line setting, discuss resources required for systemic therapy, and provide treatment recommendations stratified to four resources levels. Treatment guidelines appropriate for different resource levels offer a realistic approach to management of advanced-stage NSCLC, by recognising the limitations of a particular health-care system. Although there are many barriers to cancer control in low-resource coun...
Background: There are newer diagnostic and therapeutic armamentaria for primary lung cancer. Applica...
Survival for adults and children with acute lymphoblastic leukaemia has risen substantially in recen...
Lung cancer (LC) is the most common malignancy responsible for 1.8 million of deaths worldwide. Lung...
Stage III NSCLC represents a heterogeneous disease for which optimal treatment continues to pose a c...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidel...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidel...
Lung cancer is the second most common cancer and leading cause of cancer mortality worldwide. Recent...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidel...
Abstract Background Data are scarce regarding real-world health care resource use (HCRU) for non-sma...
Non-small cell lung cancer is the leading cause of cancer deaths globally and also in Latin America....
Lung cancer has been the most common cancer in the world for several decades. The non-small cell lun...
The management of advanced nonsmall cell lung cancer (NSCLC) patients is becoming increasingly compl...
Background: Lung cancer management is getting more complex due to the rapid advances in all aspects ...
Daily-practice challenges in oncology have been intensified by the approval of immune checkpoint inh...
AbstractLung cancer is the most common cancer worldwide and the fifth most common cause of death glo...
Background: There are newer diagnostic and therapeutic armamentaria for primary lung cancer. Applica...
Survival for adults and children with acute lymphoblastic leukaemia has risen substantially in recen...
Lung cancer (LC) is the most common malignancy responsible for 1.8 million of deaths worldwide. Lung...
Stage III NSCLC represents a heterogeneous disease for which optimal treatment continues to pose a c...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidel...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidel...
Lung cancer is the second most common cancer and leading cause of cancer mortality worldwide. Recent...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidel...
Abstract Background Data are scarce regarding real-world health care resource use (HCRU) for non-sma...
Non-small cell lung cancer is the leading cause of cancer deaths globally and also in Latin America....
Lung cancer has been the most common cancer in the world for several decades. The non-small cell lun...
The management of advanced nonsmall cell lung cancer (NSCLC) patients is becoming increasingly compl...
Background: Lung cancer management is getting more complex due to the rapid advances in all aspects ...
Daily-practice challenges in oncology have been intensified by the approval of immune checkpoint inh...
AbstractLung cancer is the most common cancer worldwide and the fifth most common cause of death glo...
Background: There are newer diagnostic and therapeutic armamentaria for primary lung cancer. Applica...
Survival for adults and children with acute lymphoblastic leukaemia has risen substantially in recen...
Lung cancer (LC) is the most common malignancy responsible for 1.8 million of deaths worldwide. Lung...